Shatavari for Health & Longevity

Created on 11/12/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Unknown – Audit

Shatavari is a traditional Indian root herb used as an oral dietary supplement for midlife hormonal balance and stress resilience. Short, mostly manufacturer-backed trials show concentrated extracts consistently relieve hot flashes, night sweats, and sleep disruption, with net benefits for stress and female sexual function, while muscle growth, bone density, and lifespan claims lack support. Verified extracts are well tolerated short-term; unverified powders risk heavy-metal contamination. (Full Review)

Protocol

Standardized extract dosing (modern clinical approach)
100–500 mg/day
100 mg (> 5% shatavarin IV), 300 mg (> 10% shatavarins), or 250–500 mg (> 30% saponins); 1,000 mg/day in musculoskeletal trials
Single versus split daily dosing
Once or twice daily
100 or 300 mg once-daily capsules, or 250–500 or 600 mg/day split twice daily; no head-to-head regimen trials
Time of day
Post-breakfast, or morning and evening post-meal
Blunts saponin nausea without daytime sedation; meal pairing reflects trial regimens and common integrative practice
Time to effect
Menopausal and Perimenopausal Symptom Relief
4–8 weeks
Symptom reductions emerged at 4 weeks and deepened at 8 weeks; studied up to 24 weeks
Psychological Stress, Anxiety, and Mood Resilience
4–12 weeks
Perceived-stress reductions progressed from week 4 through week 12 in positive trials
Gastric Emptying and Upper Gastrointestinal Motility
Single oral dose
Accelerated gastric emptying after single oral doses in a small crossover trial

Benefits

Contraindications
  • Pregnant individuals
  • Individuals with Asparagaceae or culinary asparagus allergy
  • Individuals with estrogen-receptor-positive breast, endometrial, or ovarian cancer or untreated endometrial hyperplasia
Key Interactions
Theoretical (inferred from mechanism)
  • Selective estrogen receptor modulators (tamoxifen) and aromatase inhibitors (letrozole)
  • Systemic estrogens and hormonal contraceptives (estradiol, ethinylestradiol)
  • Loop and thiazide diuretics (furosemide, hydrochlorothiazide)
  • Antidiabetic agents (metformin)
  • Oral over-the-counter gastrointestinal agents and narrow-window medications (omeprazole, levothyroxine)
  • Phytoestrogenic, adaptogenic, and glucose-lowering supplements (soy isoflavones, Withania somnifera, berberine)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mild gastrointestinal discomfort; heavy metal contamination in unverified products; Asparagaceae hypersensitivity and allergic reactions
  • Speculative: Teratogenicity and fetal growth restriction; estrogen-sensitive tissue stimulation; supratherapeutic diuresis and electrolyte shift

Monitoring

Marker Target Why
Venous blood lead < 5 µg/dL Safety check for unverified imported powders
Serum estradiol No established target; change from individual baseline within sex- and stage-specific reference intervals Expected-change and safety check against unexpected surges
Serum FSH No established target; directional change from individual baseline Expected-change marker alongside estradiol
Morning serum cortisol 6–23 µg/dL (standard reference range) Expected-change marker for morning decline
Serum CTX No established target; directional reduction from individual baseline Expected-change marker in 24-week bone protocols

Cadence: Baseline, week 8, week 24 during continued use, and every 6–12 months across extended cyclical regimens (venous blood lead repeated at 4–8 weeks for uncertified imported powders).

Qualitative Assessment

  • Symptom and sleep logs: Daily hot flashes, night sweats, and sleep continuity from baseline through week 8.
  • Standardized questionnaires: Self-scored Menopause Rating Scale, Perceived Stress Scale, or Female Sexual Function Index tracked at baseline, week 4, and week 8.
  • Tolerability: Absence of post-dose nausea, loose stools, breast tenderness, or unexpected uterine bleeding.